A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.

The FDA, on Wednesday, unexpectedly placed two of Regenxbio's experimental gene therapies on hold after a patient developed a ...

An AAV vector genome integration event associated with PLAG1 overexpression was identified in a preliminary analysis of the resected tumor.

The US Food and Drug Administration (FDA) has placed a clinical hold on Regenxbio’s investigational gene therapy, RGX-111, ...

As of Wednesday, January 28, REGENXBIO Inc.’s RGNX share price has dipped by 18.49%, which has investors questioning if this is right time to buy.

The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...

REGENXBIO shares sink after the FDA places a clinical hold on two gene therapy trials following a safety concern tied to ...

The FDA halted clinical trials of two gene therapies on account of a tumor found in a Hurler syndrome patient who had received RGX-111.

The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which ...

The FDA paused trials for two experimental gene therapies from Regenxbio after one child developed a brain tumor, the company ...

The company said that the FDA hold has impacted two experimental gene therapies, RGX-111 and RGX-121. ・REGENXBIO added that ...

Shares of Regenxbio plunged after the Food and Drug Administration placed clinical holds on two drug development programs ...